MEMENTO-VAScular COmponents of Dementia (VASCOD)

A Multicenter national longitudinal cohort study including at least 800 individuals recruited from French Research Memory Centers and followed up over 36 months and included in Memento.

Study Overview

• Status: Completed
• Conditions: Alzheimer's Disease (AD); Alzheimer's Disease (AD) Related Disorders
• Intervention / Treatment: Other: in Memento-VASCOD

Detailed Description

Alzheimer's disease (AD) is a neurodegenerative disorder thought to be caused by the accumulation of the peptide amyloid beta and the hyperphosphorylated tau protein in the brain. There are increasing arguments in favor of an important role of vascular damages in the development and progression of AD.

The time course of these vascular alterations and how they relate to dementia and AD pathology remain unclear, as no protocol that allows the development of the diverse vascular pathology to be scored, and hence to be tracked with ageing, has so far been developed and widely validated. The aims of this project are to investigate, in a large clinical sample of patients presenting either isolated cognitive complaints or light to mild cognitive deficits, how vascular risk factors and vascular alterations (assessed at macro and micro levels) relate to cerebrovascular disease and cognitive decline.

The primary objective of this ancillary study is to investigate the prospective association between vascular risk factors, inflammation markers and vascular damages on cognitive decline and neurodegeneration progression over up to 4 years of follow-up in a sample of individuals presenting with a spectrum of cognitive profiles ranging from isolated cognitive complaints to cognitive deficits without dementia.

The secondary objectives are the following

• To investigate the role of vascular risk factors (diabetes, hypertension, hypercholesterolemia) and vascular damages on progression to clinical dementia over up to 4-year follow-up.
• To study whether the interaction between changes in markers of macrovascular and microvascular structures on cognitive deficits progression.
• To study the association between in BP, hypertension, antihypertensive treatments and vascular damages, progression of cerebrovascular disease seen at MRI and cognitive decline and dementia risk
• To assess the temporality of vascular damages burden on neurodegeneration
• To assess the association between retinal vasculature defect and brain neurovascular damages
• To study the link between vascular damages and AD pathology (Cerebro-Spinal Fluid (CSF) and Positron emission tomography (TEP) amyloid imaging) biomarkers in the subsample of participants having all measures available
• To investigate how inflammatory markers mediate the association between vascular damages and neurodegeneration
• To assess whether vascular factors and neurodegenerative factors act independently or synergistically on the course of cognitive decline
• To assess simultaneously the impact of vascular damages on end organs (brain, eye, and kidney)
• To study the correlation between cerebral blood flow, measured by Arterial spin-Labeled (ASL) MRI and cognitive decline
• To study whether genetic polymorphisms revealed from genome-wide association studies (GWAS) of AD of vascular factors could modulate the association between vascular damages and cognitive decline

• Study Type: Interventional
• Enrollment (Actual): 332
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Amiens, France
    • CHU d'Amiens
  • Bordeaux, France, 33000
    • CHU de Bordeaux - Pellegrin
  • Dijon, France
    • CHU de Dijon
  • Lille, France
    • CHU de Lille
  • Lyon, France
    • Hospices Civils de Lyon
  • Marseille, France
    • AP-HM
  • Montpellier, France
    • CHU de Montpellier
  • Paris, France
    • AP-HP - Hôpital Lariboisière
  • Paris, France
    • AP-HP - Hôpital BROCA
  • Strasbourg, France
    • CHU de Strasbourg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 48 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Participants to MEMENTO-Vascod should be included in MEMENTO.
• To have signed a specific MEMENTO-Vascod informed consent form, prior to any Vascod ancillary study related procedures
• To be aged 50 years old and above
• To have a Clinical Dementia Rating scale <0.5 and to be not demented;

Exclusion Criteria:

• Are under guardianship
• Live in skilled nursing facility
• Are Pregnant or breast feeding women
• Meet brain MRI exclusion criteria (Same criteria as in Memento main protocol)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Alzheimer's disease and related disorders

Other: in Memento-VASCOD; Pulse wave velocity assessment; Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences; Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement; Neuropsychological testing and behaviorial and mood scales; Urinary albumin excretion measurement

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in cognitive performances over	36 months from baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression to clinical dementia of Alzheimer's type according to standardized criteria	standardized criteria : Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and National Institute of Neurological and Communicative Disorders and Stroke Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) classifications	36 months from baseline
Change in CSF and blood amyloid biomarkers of AD		24 months from baseline
Change in brain atrophy and hippocampal volumes		24 months from baseline
Progression of small vessels disease markers (white matter lesions, lacunar infarcts, microbleeds)		24 months from baseline

Collaborators and Investigators

• Sponsor: University Hospital, Bordeaux
• Collaborators: Ministry for Health and Solidarity, France
• Investigators: Principal Investigator: Genevieve CHENE, Prof, CIC-EC1401 - ISPED - CHU de Bodeaux; Study Chair: Geneviève CHENE, Prof, CIC-EC1401 - ISPED - CHU de Bordeaux; Study Director: Carole DUFOUIL, Director, CIC-EC1401 - ISPED - CHU de Bordeaux

Study record dates

Study Major Dates

• Study Start (Actual): November 4, 2014
• Primary Completion (Actual): October 29, 2021
• Study Completion (Actual): October 29, 2021

Study Registration Dates

• First Submitted: October 1, 2014
• First Submitted That Met QC Criteria: October 14, 2014
• First Posted (Estimate): October 15, 2014

Study Record Updates

• Last Update Posted (Actual): January 28, 2022
• Last Update Submitted That Met QC Criteria: January 27, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Keywords: Alzheimer's disease; Mild Cognitive Impairment
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Tauopathies; Dementia; Alzheimer Disease
• Other Study ID Numbers: CHUBX 2012/32